摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,3S,4R,5R) 3-azido-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-carboxylic acid methylamide | 786665-77-8

中文名称
——
中文别名
——
英文名称
(2S,3S,4R,5R) 3-azido-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-carboxylic acid methylamide
英文别名
3-azido-5-(6-methylaminopurin-9-yl)-4-hydroxy-tetrahydro-furan-2-carboxylic acid methyl amide;(2S,3S,4R,5R)-3-azido-4-hydroxy-N-methyl-5-[6-(methylamino)purin-9-yl]oxolane-2-carboxamide
(2S,3S,4R,5R) 3-azido-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-carboxylic acid methylamide化学式
CAS
786665-77-8
化学式
C12H15N9O3
mdl
——
分子量
333.31
InChiKey
DHYPOFDIQJEGKY-HIFLKKFUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    129
  • 氢给体数:
    3
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds for the treatment of ischemia
    申请人:DeNinno P. Michael
    公开号:US20050171049A1
    公开(公告)日:2005-08-04
    A 3 agonists having Formula I are described herein as well as methods of using such A 3 agonists and pharmaceutical compositions containing such A 3 agonists. The A 3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.
    本文描述了具有I式的A3激动剂,以及使用这种A3激动剂的方法和含有这种A3激动剂的制药组合物。这些A3激动剂对于减少由组织缺血或缺氧引起的组织损伤是有用的。
  • 3‘-Aminoadenosine-5‘-uronamides:  Discovery of the First Highly Selective Agonist at the Human Adenosine A<sub>3</sub> Receptor
    作者:Michael P. DeNinno、Hiroko Masamune、Lois K. Chenard、Kenneth J. DiRico、Cynthia Eller、John B. Etienne、Jeanene E. Tickner、Scott P. Kennedy、Delvin R. Knight、Jimmy Kong、Joseph J. Oleynek、W. Ross Tracey、Roger J. Hill
    DOI:10.1021/jm0255724
    日期:2003.1.1
    Selective adenosine A(3) agonists have potential utility for the prevention of perioperative myocardial ischemic injury. Herein, we report on the discovery and synthesis of compound 7. This amino nucleoside agonist possesses unprecedented levels of selectivity for the human adenosine A(3) receptor.
  • Design and synthesis of 3′-ureidoadenosine-5′-uronamides: effects of the 3′-ureido group on binding to the A3 adenosine receptor
    作者:Lak Shin Jeong、Myong Jung Kim、Hea Ok Kim、Zhan-Guo Gao、Soo-Kyung Kim、Kenneth A. Jacobson、Moon Woo Chun
    DOI:10.1016/j.bmcl.2004.07.042
    日期:2004.10
    On the basis of high binding affinity at the A(3) adenosine receptor of 3'-aminoadenosine derivatives with hydrogen bonding donor ability, novel 3'-ureidoadenosine analogues were synthesized from 1,2:5,6-di-O-isopropylidene-D-glucose in order to lead to stronger hydrogen bonding than the corresponding 3'-aminoadeno sine derivatives. However, the synthesized 3'-ureidoadenosine analogues were totally devoid of binding affinity, because 3'-urea moiety caused steric and electrostatic repulsions at the binding site of the A(3) adenosine receptor, leading to conformational distortion. (C) 2004 Elsevier Ltd. All rights reserved.
  • Orthogonal Activation of the Reengineered A<sub>3</sub> Adenosine Receptor (Neoceptor) Using Tailored Nucleoside Agonists
    作者:Zhan-Guo Gao、Heng T. Duong、Tatiana Sonina、Soo-Kyung Kim、Philippe Van Rompaey、Serge Van Calenbergh、Liaman Mamedova、Hea Ok Kim、Myong Jung Kim、Ae Yil Kim、Bruce T. Liang、Lak Shin Jeong、Kenneth A. Jacobson
    DOI:10.1021/jm050968b
    日期:2006.5.1
    An alternative approach to overcome the inherent lack of specificity of conventional agonist therapy can be the reengineering of the GPCRs and their agonists. A reengineered receptor ( neoceptor) could be selectively activated by a modified agonist, but not by the endogenous agonist. Assisted by rhodopsin-based molecular modeling, we pinpointed mutations of the A(3) adenosine receptor (AR) for selective affinity enhancement following complementary modifications of adenosine. Ribose modifications examined included, at 3' : amino, aminomethyl, azido, guanidino, ureido; and at 5' : uronamido, azidodeoxy. N-6-Variations included 3-iodobenzyl, 5-chloro-2-methyloxybenzyl, and methyl. An N-6-3-iodobenzyl-3'-ureido adenosine derivative 10 activated phospholipase C in COS-7 cells (EC50 = 0.18 mu M) or phospholipase D in chick primary cardiomyocytes, both mediated by a mutant ( H272E), but not the wild-type, A(3)AR. The affinity enhancements for 10 and the corresponding 3'-acetamidomethyl analogue 6 were > 100-fold and > 20-fold, respectively. 10 concentration-dependently protected cardiomyocytes transfected with the neoceptor against hypoxia. Unlike 10, adenosine activated the wild-type A(3)AR (EC50 of 1.0 mu M), but had no effect on the H272E mutant A(3)AR (100 mu M). Compound 10 was inactive at human A(1), A(2A), and A(2B)ARs. The orthogonal pair comprising an engineered receptor and a modified agonist should be useful for elucidating signaling pathways and could be therapeutically applied to diseases following organ-targeted delivery of the neoceptor gene.
查看更多